Navigation Links
ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
Date:5/15/2008

TUCSON, Ariz., May 15 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX), a biopharmaceutical company developing and commercializing therapies for vascular disorders, today reported financial results for the first quarter ended March 31, 2008 and discussed recent corporate highlights.

Corporate Highlights:

-- Entered into agreement with Abbott Laboratories satisfying remaining

debt obligation under non-recourse promissory note issued in connection

with the Company's urokinase acquisition.

-- Signed letter of intent to sell urokinase inventory and related assets

to Microbix Biosystems for $17 million in cash: $12 million at closing

and $5 million upon achievement of an inventory stability milestone.

-- Identified strategic funding to continue advancement of its core

SonoLysis program upon closing of urokinase divestiture with Microbix

Biosystems.

Bradford A. Zakes, President and CEO of ImaRx stated, "Through the satisfaction of our debt obligation with Abbott under favorable terms and the pending divestiture of our urokinase asset to Microbix, we will have successfully gained access to operating capital that is non-dilutive to our shareholders. Taken together, these events have provided us the strategic alternative to continue the advancement of our core SonoLysis technology within ImaRx."

Financial Results

Revenue for the first quarter ended March 31, 2008 rose to $1.9 million from $1.2 million for the first quarter ended March 31, 2007. Increased sales of urokinase, which ImaRx began commercializing in October 2006, drove the revenue increase for the quarter.

Net loss for the first quarter of 2008 was $2.5 million compared to a net loss of $2.4 million for the same period last year. This change was primarily a result of increased selling, general and administrative expenses offset partially by increased urokinase sales. Net loss per share attributable to common shareholders for the first quarter of 2008 was $0.25 based on weighted average shares of approximately 10.0 million, compared to net loss per share attributable to common shareholders in the same period last year of $1.09 based on weighted average shares of approximately 2.6 million.

Cost of product sales for the first quarter of 2008 totaled $0.8 million compared to $0.5 million for the first quarter of 2007. The cost of product sales includes the price paid to acquire the urokinase inventory as well as labeling costs directly incurred in bringing the product to market.

Research and development expenses for the first quarter of 2008 increased to $1.6 million from $1.5 million in the prior year period. This increase was principally a result of increased outside contract work performed on grants and stock-based compensation expense, partially offset by reduced contract manufacturing and pre-clinical study costs.

General and administrative expenses for the first quarter of 2008 increased to $2.0 million from $1.4 million for the same period last year resulting mainly from an increase in outside accounting and audit fees related to maintaining public company status, expenses related to marketing materials for the re-branding of urokinase under the Kinlytic(TM) brand name, salaries for additional sales and general administrative staff offset partially by a decrease in amortization expense due to the trade name being fully amortized prior to 2008.

On March 31, 2008, ImaRx had $10.3 million in cash and cash equivalents compared to $12.9 million in cash and cash equivalents on December 31, 2007. The decrease in the cash balance was primarily related to cash used in performing operating activities. Subsequent to the end of the quarter, the Company paid $5.2 million to satisfy all outstanding liabilities to Abbott Laboratories, including the $10.8 million balance on the $15 million non-recourse note. ImaRx also recently signed a letter of intent to sell its urokinase assets to Microbix Biosystems for $17 million in cash. Since signing the agreement with Abbott and assuming the transaction with Microbix closes, management believes that there will be sufficient cash resources for at least the next 12 months.

Conference Call and Webcast Information

Management will host a conference call to review financial results for the quarter ended March 31, 2008 and recent business developments. The call is scheduled for today, May 15, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). To participate in the live conference call, U.S. residents should dial 877-407-4018, and international callers should dial 201-689-8471. Alternatively, log on to http://www.imarx.com to access a live webcast of the call. Please connect to the Investor section of ImaRx's website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary. To access the 48-hour telephone replay, U.S. residents should dial 877-660-6853, and international callers should dial 201-612-7415. The account number for the replay is 3055, and the conference ID number is 284385. A replay of the webcast will also be available on http://www.imarx.com 14-days following the call.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.

About SonoLysis

ImaRx's SonoLysis program involves the administration of its proprietary MRX-801 microbubbles and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The sub-micron size of MRX-801 microbubbles may allow them to penetrate a blood clot, so that when ultrasound is applied their expansion and contraction, or cavitation, can break the clot into very small particles. This technology was most recently evaluated in a Phase I/II clinical trial in combination with tPA in patients suffering from acute ischemic stroke.

About Urokinase

Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercialized for more than 20 years and has been administered to greater than four million patients. In 2006, ImaRx acquired urokinase and all related assets, including an approximate four-year supply of inventory, cell lines and manufacturing rights to the drug. Since October 2006, ImaRx has been selling its urokinase inventory in the U.S. market where it is estimated to be listed on pharmacy formularies at approximately 700 acute care hospitals and has generated $16.7 million in net proceeds through the first quarter of 2008.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include those related to the Company's expectation that: it will continue advancement of its core SonoLysis program upon closing of urokinase divestiture with Microbix Biosystems; it will close the transaction with Microbix; and the Company's belief that it will have sufficient cash resources for at least the next 12 months. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. A more complete description of these risks and the event that may cause such events not to occur can be found in the Company's filings with the Securities and Exchange Commission. All information in this press release is as of May 15, 2008, and the Company undertakes no duty to update this information.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

sephraim@theruthgroup.com

jrando@theruthgroup.com

ImaRx Therapeutics, Inc.

Consolidated Statements of Operations

(in thousands except share and per share data)

Three Months Ended

March 31

2007 2008

(unaudited)

Revenues:

Product sales, net $1,086 $1,849

Research and development 122 95

Total operating revenue 1,208 1,944

Costs and expenses:

Cost of product sales 461 834

Research and development 1,541 1,567

General and administrative 1,420 1,994

Total cost and expenses 3,422 4,395

Operating loss (2,214) (2,451)

Interest and other income, net 41 94

Interest expense (225) (173)

Net loss (2,398) (2,530)

Accretion of dividends on preferred stock (441) -

Net loss attributed to common stockholders $(2,831 $(2,530)

Net loss per share:

- Basic and diluted $(1.09) $(0.25)

Shares used in computing net loss per share:

- Basic and diluted 2,605,915 10,046,683

ImaRx Therapeutics, Inc.

Selected Balance Sheet Data (in thousands)

December 31, March 31,

2007 2008

ASSETS (unaudited)

Current assets:

Cash and cash equivalents $12,861 $10,293

Restricted cash 388 -

Accounts receivable, net 349 124

Inventory 11,138 10,791

Inventory subject to return 2,560 2,144

Prepaid expenses and other 589 320

Total current assets 27,885 23,672

Long-term assets:

Property and equipment, net 1,170 1,046

Intangible assets, net 1,633 1,459

Other assets 19 19

Total assets $30,707 $26,196

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $1,277 $1,213

Accrued expenses 837 593

Accrued chargebacks and administrative fees 1,317 1,251

Deferred revenue 5,373 4,471

Notes payable 11,698 10,749

Other - 40

Total current liabilities 20,502 18,317

Other long-term liability - -

Total liabilities 20,502 18,317

Total stockholders' equity 10,205 7,879

Total liabilities and stockholders' equity $30,707 $26,196


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Postpones Release of First Quarter 2008 Financial Results
2. ImaRx Schedules Release of First Quarter 2008 Financial Results
3. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
4. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
5. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
6. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
7. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
8. ImaRx to Report Corporate Updates and 4Q07 Financial Results
9. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
10. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Nile Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):